# MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)

> **NCT02865616** · PHASE1 · COMPLETED · sponsor: **NuBiyota** · enrollment: 19 (actual)

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** MET-2
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT02865616
- **Lead sponsor:** NuBiyota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-27
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-03-17
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02865616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02865616, "MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02865616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*